Provided by Tiger Fintech (Singapore) Pte. Ltd.

EVEREST MED-B

58.450
+1.6502.90%
Volume:4.97M
Turnover:283.29M
Market Cap:19.11B
PE:-16.90
High:59.450
Open:55.500
Low:54.850
Close:56.800
Loading ...

Stock Track | Everest Medicines Plummets 5.09% Despite Strong Revenue Growth, as Net Loss Concerns Investors

Stock Track
·
26 Mar

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2024

THOMSON REUTERS
·
26 Mar

Press Release: Everest Medicines Announces Financial Results for Full Year Ended December 31, 2024

Dow Jones
·
26 Mar

BRIEF-Everest Medicines Posts FY Net Income RMB -1,041.4 Million

Reuters
·
26 Mar

Everest Medicines FY Revenue RMB 706.7 Million

THOMSON REUTERS
·
26 Mar

Everest Medicines Announces FDA Clearance of Ind Application for Tumor-Associated Antigen Vaccine Evm14

THOMSON REUTERS
·
24 Mar

High Growth Tech Stocks in Asia to Watch for Promising Growth

Simply Wall St.
·
10 Mar

Everest Medicines Shares Surge 18% as First Patient Dosed in Cancer Drug Trial

MT Newswires Live
·
07 Mar

Everest Medicines Announces First Patient Dosed With Evm16, Its First Internally Developed Personalized Mrna Cancer Vaccine

THOMSON REUTERS
·
06 Mar

Everest Medicines Ltd - Evm16 Shows Synergistic Effect With Pd-1 Antibody in Preclinical Data

THOMSON REUTERS
·
06 Mar

Everest Medicines Ltd - Evm16 Well Tolerated and Safe in Preclinical Toxicity Studies

THOMSON REUTERS
·
06 Mar

Everest Medicines Limited's (HKG:1952) biggest owners are retail investors who got richer after stock soared 3.8% last week

Simply Wall St.
·
03 Mar

Stock Track | Everest Medicines Plummets 5.04% on Controlling Shareholder's Block Trade

Stock Track
·
09 Jan

Everest Medicines Clarifies Unusual Price, Trading Volume Movements

MT Newswires Live
·
09 Jan

Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1B/2a Clinical Trial of Ever001, a Novel Btk Inhibitor for the Treatment of Primary Membranous Nephropathy

THOMSON REUTERS
·
04 Dec 2024

Everest Medicines to Hold Investor Calls on Data Results From Ever001 Phase 1B/2a Clinical Study in Primary Membranous Nephropathy

THOMSON REUTERS
·
27 Nov 2024

BRIEF-Everest Medicines Says PwC Agreed To Resign As Auditors Of Co

Reuters
·
15 Nov 2024

Everest Medicines- Pwc Agreed to Resign as Auditors of Co From 15 Nov

THOMSON REUTERS
·
15 Nov 2024

Stock Track | Retail Investors Cash in as Everest Medicines Stock Surges 41% Last Week

Stock Track
·
25 Oct 2024

Retail investors in Everest Medicines Limited (HKG:1952) are its biggest bettors, and their bets paid off as stock gained 41% last week

Simply Wall St.
·
25 Oct 2024